12:00 AM
Oct 19, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PH-10: Completed Phase II enrollment

Provectus completed enrollment of 30 patients in an open-label, U.S. Phase II trial evaluating topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis on...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >